<DOC>
	<DOCNO>NCT02951845</DOCNO>
	<brief_summary>The purpose study assess oral bioavailability two tablet formulation JNJ-54416076 relative suspension formulation investigate effect high fat meal pharmacokinetics tablet formulation healthy participant .</brief_summary>
	<brief_title>Study Investigate Food Effect Oral Bioavailability Tablet Formulations Relative Suspension Formulation JNJ-54416076 Healthy Participants</brief_title>
	<detailed_description />
	<criteria>Before randomization , woman must : 1 ) Postmenopausal , define ) Greater ( &gt; ) 45 year age amenorrhea great equal ( &gt; = ) 18 month , b ) &gt; 45 year age amenorrhea least 6 month less ( &lt; ) 18 month serum follicle stimulate hormone ( FSH ) level &gt; 40 International unit per liter ( IU/L ) , 2 ) Surgically sterile due hysterectomy , bilateral oophorectomy , bilateral tubal occlusion/ligation procedure , 3 ) All woman must negative serum pregnancy test Screening ; Day 1 treatment period Men ( include vasectomy ) must agree use condom even partner pregnant ( ensure fetus expose study drug vaginal absorption ) donate sperm study 3 month receive last dose study drug . Male participant encourage female partner use effective method ( example ( eg ) , prescription oral contraceptive , contraceptive injection , intrauterine device , contraceptive patch ) contraception addition condom use male study participant Healthy basis physical examination , medical history , vital sign , clinical laboratory test , 12lead electrocardiogram ( ECGs ) perform . If result abnormal , participant may include investigator judge abnormalities deviation normal clinically significant except liver function hematology test . This determination must record participant 's source document initial investigator Body Mass Index ( BMI ) 18.5 29.9 kilogram per square meter ( kg/m^2 ) ( inclusive ) body weight &gt; = 50 kilogram Blood pressure ( participant sit 5 minute ) 90 140 millimeter mercury ( mmHg ) systolic , inclusive , 50 90 mmHg diastolic , inclusive Screening Days 2 1 Period 1 . If blood pressure range , 2 repeat assessment permitted History , currently active , significant illness medical disorder , include ( limited ) cardiovascular disease ( include cardiac arrhythmia , myocardial infarction , stroke , peripheral vascular disease ) , endocrine metabolic disease ( eg , hyper/hypothyroidism ) , hematological disease ( eg , von Willebrand 's disease bleeding disorder ) , respiratory disease , hepatic gastrointestinal disease , neurological psychiatric disease , ophthalmologic disorder ( include retinal disorder cataract ) , neoplastic disease , skin disorder , renal disorder , illness investigator considers exclude participant could interfere interpretation study result History Gilbert 's disease , DubinJohnson Rotor syndrome , family history liver gallbladder disease may suggest underlie genetic disorder Aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , gammaglutamyltransferase ( GGT ) , bilirubin level ( indirect , direct ) , alkaline phosphatase upper limit normal ( ULN ) clinical laboratory 's reference range Screening Day 1 Period 1 Hemoglobin , hematocrit , red blood cell count lower limit normal clinical laboratory 's reference range Screening . On Day 1 Period 1 , participant hemoglobin , hematocrit , red blood cell count lower limit normal laboratory 's reference range , participant may include investigator judge abnormality deviation reference clinically significant History cholecystectomy gallbladder disease Known allergy , hypersensitivity , intolerance excipients formulation Any condition , opinion investigator , participation would best interest participant ( example , compromise wellbeing ) could prevent , limit , confound protocolspecified assessment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>